Get started
Author

Avinash Khanna

Observed names: A. Khanna, Avinash Khanna (19276406)
ORCID: 0000-0003-0471-8573
Observed ORCID: 0000-0003-0471-8573
OpenAlex ID: A5001854130
Carbenylative Amination with N-Tosylhydrazones
2012 · Avinash Khanna, Charles Maung, et al. · Organic Letters · 92
Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme–Product Complex
2013 · Andrew Chang, Johannes Schiebel, et al. · Biochemistry · 59
Structural and functional analysis of two di-domain aromatase/cyclases from type II polyketide synthases
2015 · Grace Caldara-Festin, David R. Jackson, et al. · Proceedings of the National Academy of Sciences · 41
PDF
Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time
2020 · Avinash Khanna, Alexandre Côté, et al. · ACS Medicinal Chemistry Letters · 37
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2024 · Patricia J. Keller, Elizabeth J. Adams, et al. · Cancer Research · 36
Palladium-Catalyzed Catellani Aminocyclopropanation Reactions with Vinyl Halides
2013 · Avinash Khanna, Ilandari Dewage Udara Anulal Premachandra, et al. · Organic Letters · 30
Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors
2020 · Victor S. Gehling, John P. McGrath, et al. · ACS Medicinal Chemistry Letters · 22
Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity
2021 · Jacob I. Stuckey, Nico R. Cantone, et al. · Journal of Biological Chemistry · 18
PDF
Substituted Diphenyl Ethers as a Novel Chemotherapeutic Platform against Burkholderia pseudomallei
2013 · Jason E. Cummings, Adam J. Beaupre, et al. · Antimicrobial Agents and Chemotherapy · 14
Pd-Catalyzed Bis-cyclization/Dimerization Reactions of ω-Aminovinyl Halides
2013 · Avinash Khanna, Ilandari Dewage Udara Anulal Premachandra, et al. · Organic Letters · 9
Strategic Use of Benzylic Alcohols Reveals Cryptic Hydrogen-Bonding Interactions: Discovery of HBC-12551 as a Potent Noncovalent Bruton’s Tyrosine Kinase Inhibitor
2026 · Gang Liu, Shuaishuai Liu, et al. · Journal of Medicinal Chemistry · 2
Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Figure S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Table S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Figure S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Table S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Table S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Figure S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Table S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Table S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Figure S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Table S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Table S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Works count: 55
Citation count: 360
H-index: 9
I10-index: 9
Year
Topic
Type